Drugs / MNC-168
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05383703 | Oct 2022 → Jul 2024 | cancer | Moon (Guangzhou) Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNC-168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05383703 ↗ |
| Known as | Therapy of Live bacteria MNC-168 | “Therapy of Live bacteria MNC-168” NCT05383703 ↗ |
| Modality | Other / unclassified | “live bacterium MNC-168” NCT05383703 ↗ |
| Route | Oral | “single oral agent” NCT05383703 ↗ |